A 58-year-old man with chronic heart failure (LVEF 32%) and hypertension presents with persistent dyspnea on exertion despite 6 weeks of therapy with lisinopril 10 mg daily and furosemide 40 mg daily. Physical examination reveals bibasal crackles and elevated JVP. Echocardiography confirms no change in ejection fraction. What is the most appropriate next step in management?

Explanation

## Clinical Context This patient has symptomatic HF with reduced ejection fraction (HFrEF) despite ACE inhibitor monotherapy. He requires optimization of guideline-directed medical therapy (GDMT) before considering advanced interventions. ## Next Step Rationale **Key Point:** The patient is on suboptimal therapy. After ACE inhibitor initiation, the next evidence-based step is to add a beta-blocker AND an aldosterone antagonist (spironolactone), while optimizing diuretic dosing for symptom relief. **High-Yield:** The classic GDMT sequence for HFrEF is: 1. ACE inhibitor (or ARB) 2. Beta-blocker (carvedilol, metoprolol succinate, bisoprolol) 3. Aldosterone antagonist (spironolactone or eplerenone) 4. ARNI (sacubitril/valsartan) if tolerated 5. SGLT2 inhibitor (dapagliflozin, empagliflozin) This patient has only received an ACE inhibitor. Adding spironolactone addresses aldosterone-mediated remodeling and reduces mortality by ~30% in HFrEF [cite:Harrison 21e Ch 297]. Increasing diuretics addresses acute congestion. ## Why This Approach Works | Drug Class | Mechanism | Mortality Benefit | Timing | | --- | --- | --- | --- | | ACE-I | Reduces afterload, blocks RAAS | ↓ 23% | First-line | | Beta-blocker | Reduces HR, contractility, RAAS | ↓ 34% | Add after ACE-I | | Aldosterone antagonist | Blocks aldosterone, reduces fibrosis | ↓ 30% | Add after ACE-I, with K+ monitoring | | Diuretic | Relieves congestion | Symptomatic relief | Titrate as needed | **Clinical Pearl:** Spironolactone requires monitoring of serum potassium and creatinine (risk of hyperkalemia, especially with ACE inhibitors), but the mortality benefit in HFrEF is well-established. ## Why Not the Other Options - **Switching ACE inhibitor classes** (option B) provides no additional benefit; the issue is incomplete GDMT, not ACE-I choice. - **Digoxin** (option C) has no mortality benefit in HFrEF and is reserved for symptomatic HF with concurrent atrial fibrillation; it does not address the underlying pathophysiology. - **Transplant referral** (option D) is premature without optimized medical therapy; most HFrEF patients improve significantly with full GDMT.